Rossari Biotech Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vtvdcmc370mn32hqp3mg0i6n.pdf

Key Takeaways


Topline & Segment Performance


Margin Dynamics & Raw Material Pass-Through

Chari: "Unlike other industries, our dependence on Middle East is not as much as the other countries. Of course prices globally have risen... from this month onwards, we have been able to pass through all our high purchase raw materials into adding margins and getting the final prices. The customers are accepting because everybody can see the global geopolitical situation."

CAPEX, Capacity & Capital Allocation

Sablok: "It is just an optimization of our spend in terms of cash flow management and the ratios that we are looking, ROCES. We would like at least the current capacity to generate some of the returns that we have earmarked, and then probably go ahead and spend on these remaining CAPEX plans."

Portfolio Restructuring & Non-Core Exits

Sablok: "The target is to actually get debt free in the next 18 months, but the time will tell. Currently, the plan is to keep bringing down our debt over the next 18 months."

Geographic & End-Market Expansion


Management Posture & Unanswered Questions

Chari: "I think there is nothing of such at all. We are all sitting, working and focusing on growth. Market rumours will come and go. There is nothing on the plan at this moment."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthMinimum 15% growth, driven by pharma, agro, oil and gas and new pharma segmentsFY27
EBITDA marginRemain at 12-13% on a consolidated basis; improvement levers from pharma expected in H2FY27
CAPEX spend₹50-75 crore, down from earlier ₹192 crore planFY27
Debt reductionBecome debt-free, funded by asset sales, product trimming and operating cash flowWithin 18 months
Institutional businessReach breakeven or profitabilityFY27
Employee cost growthGrowth rate will not continue at FY26 levelsFY27
Thailand plant contributionMeaningful revenue contribution starting with textile, then AHN and HPPCFrom Q2 FY27
Pharma product CAPEXOne pharma product CAPEX to come upSometime in FY27
Non-core asset salesMore office spaces and unutilized assets to be liquidatedDuring FY27
B2C business restructuringEvaluate restructuring or exit at good value; plan is to happen in 20272027 or longer
High-margin segment ramp-upPharma, food, personal care, cosmetics ramp-up to support margin improvementNext 2-3 years

Key Metrics

MetricQ4 FY26
Revenue from operations₹684.9 cr, +18% YoY, highest-ever quarterly revenue
EBITDA₹77.3 cr, +11% YoY, highest-ever quarterly absolute EBITDA
EBITDA margin11.3%, vs 12% in Q4 FY25
FY26 full-year revenue₹2,396.4 cr, +15% YoY
FY26 full-year EBITDA₹286 cr, +8% YoY
FY26 full-year EBITDA margin11.9%, vs 12.7% in FY25
Core B2B EBITDA margin (FY26)14%, excluding institutional and B2C businesses
HPPC segment growth18% YoY
Textiles segment growth20% YoY
AHN segment growth14% YoY
Exports growth (FY26)11% YoY
Installed ethoxylation capacity66,000 MT per annum at Dahej
Ethoxylation utilization90% to 100%, running 24/7, 365 days a year
FY27 revenue growth guidanceAt least 15% YoY, similar to FY26
FY27 EBITDA margin guidance12% to 13%
FY27 CAPEX plan₹50 cr to ₹75 cr
Long-term debt~₹200 cr, balance is short-term working capital borrowings
B2C business revenue (FY26)~₹250 cr to ₹260 cr, balance of total revenue is B2B
Top 10 customer concentration12% to 13% of revenue, no single customer more than 2%
Net income from sale of Mumbai office space₹19 cr
Raw material price increases in March25% to 30% on some raw materials
Thailand plant peak revenue potential₹50 cr to ₹75 cr
6-year sales CAGR25%
6-year profit CAGR18%